Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial
- 30 April 2012
- journal article
- research article
- Published by Elsevier BV in Pulmonary Pharmacology & Therapeutics
- Vol. 25 (2), 169-177
- https://doi.org/10.1016/j.pupt.2011.12.011
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The Metabolic Syndrome in Patients With Chronic Bronchitis and COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2009
- Biomarkers of Systemic Inflammation in Stable and Exacerbation Phases of COPDLung, 2008
- Biomarkers in COPDSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2008
- Outcomes for COPD pharmacological trials: from lung function to biomarkersEuropean Respiratory Journal, 2008
- Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigsThorax, 2007
- Biomarkers in COPD: time for a deep breathThorax, 2007
- Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity – a common inflammatory phenotype?Respiratory Research, 2006
- COPD: current therapeutic interventions and future approachesEuropean Respiratory Journal, 2005
- Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysisThorax, 2004
- The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?Inflammation Research, 2003